Patients report being unable to fill generic liraglutide 3 mg

Patients using generic liraglutide 3 mg for weight management are reporting they cannot get their prescriptions filled, according to posts in the r/liraglutide community on Reddit describing a supply gap through late May and into June 2026 ^[1]. The shortage appears specific to the five-pen cartons used for the weight-loss dose, while two-pen and three-pen cartons used for diabetes treatment have remained available ^[1].

Liraglutide is the active ingredient in the brand-name drugs Saxenda (for weight management) and Victoza (for type 2 diabetes). Generic versions have entered the US market and are dispensed based on the number of pens per carton, which corresponds to the intended dose and use. Patients posting in the community describe difficulty locating the five-pen weight-management cartons at pharmacies that otherwise have liraglutide in stock for diabetes patients ^[1].

Several patients say they eventually found supply by transferring their prescriptions between pharmacy chains and obtaining cartons labeled with the Cipla brand name ^[1]. Cipla is a manufacturer that has produced generic liraglutide, according to the reports, though the source does not specify why Cipla-labeled stock was available in some locations and not others, or how widespread the shortage is beyond the anecdotal reports shared online ^[1].

The posts do not identify a manufacturer statement, an official shortage notice, or data from the Food and Drug Administration confirming a nationwide shortage. What is described comes from patient reports in a single online forum thread, not from pharmacy chains, drug makers, or regulators ^[1].

Why it matters for patients

For people managing obesity with generic liraglutide, an interrupted supply can mean a gap in treatment while they search for a pharmacy that has stock or wait for a transferred prescription to process. The Reddit reports suggest this is not simply a matter of one pharmacy being out of stock, since patients describe checking multiple locations and chains before finding the five-pen cartons ^[1].

The fact that two-pen and three-pen diabetes cartons remained available while five-pen weight-management cartons did not suggests the gap may be tied to how manufacturers or distributors are allocating supply between the two dosing configurations, though the source does not explain the cause ^[1]. Patients who rely on the weight-management dose may need to spend extra time contacting pharmacies or asking their prescriber about transferring a prescription elsewhere, based on what other patients describe doing ^[1].

Because this account comes from a patient community rather than an official source, it is not yet known how many pharmacies or regions are affected, how long the gap will last, or whether manufacturers have acknowledged a shortage. Anyone affected should not assume the experience described by other patients online will match their own local pharmacy's situation.

What happens next

The source describes a supply gap spanning late May through June 2026, based on patient reports ^[1]. It is not known from the available reporting whether the FDA, the manufacturers of generic liraglutide, or major pharmacy chains have issued any public statement addressing the shortage, or when broader supply might be restored. Patients experiencing filling problems may want to watch for updates from their pharmacy or prescriber, since no official timeline for resolution is available in the source reviewed here ^[1].